EUVIMEDEUVIMED entdecken
Multizentrische Studie

Health‐Related Quality of Life and Symptom Burden in Pediatric Patients Receiving CAR T‐Cell Therapy: A Prospective, Longitudinal Patient‐Reported Outcomes Study

Angela Steineck iD, Liyun Zhang, Amy Y Pan, Mallory R Taylor iD, Sara K Silbert, Haneen Shalabi, Liam Comiskey, Jennifer M Knight, Lori Wiener iD, Deena Levine

Pediatric Blood & Cancer · 2026-10 · 73 (10)

DOI: 10.1002/1545-5017.70589 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 31.07.2026. Verfasst von Angela Steineck und 9 weiteren Autor:innen. Beteiligte Einrichtung: MACC Fund Center for Cancer and Blood Disorders, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Quality of Life, Patient Reported Outcome Measures, Immunotherapy, Adoptive, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit nennt 42 Literaturangaben. Gefördert von: T32 Training, St. Baldrick's Foundation, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chimeric antigen receptor (CAR) T‐cell therapy has expanded rapidly as an investigational treatment for advanced cancers. Studies in acute lymphoblastic leukemia (ALL) suggest health‐related quality of life (HRQOL) may improve by 1‐month post‐infusion. However, patient‐reported outcomes remain insufficiently characterized, particularly across the broader pediatric CAR T‐cell population. Procedure English‐ or Spanish‐speaking patients (ages 8–25 years) receiving CAR T‐cell therapy for any malignancy were recruited from three US pediatric cancer centers. Patient‐reported HRQOL (PedsQL) and symptom burden (Memorial Symptom Assessment Scale [MSAS]) were assessed serially through 12 months post‐infusion, emphasizing the first month. Linear mixed models characterized score trajectories and examined associations between symptom burden and HRQOL.

Results

Fifty‐nine patients completed baseline HRQOL assessments; 41% were treated for ALL. Median age was 17 years and 46% identified as female. Participants completed a median of six assessments, with nearly 75% obtained within the first month. Scores were worst at baseline (mean [SD]: PedsQL Generic: 64.9 [18.4], PedsQL Cancer: 70.0 [16.2], MSAS: 24.4 [19.4]) and improved post‐infusion. The greatest gains from baseline to 4 weeks were seen in physical functioning (mean + 8) and worry (mean + 20). Across all timepoints, the most burdensome symptoms were fatigue, worry, pain, nervousness, and anorexia. Symptom burden demonstrated a strong negative correlation with HRQOL ( r = – 0.81, p < 0.0001).

Conclusions

Pediatric patients undergoing CAR T‐cell therapy experience generally favorable HRQOL trajectories and modest, time‐limited symptom burden. Serial patient‐reported outcome collection is feasible in this population and provides actionable insight to guide supportive care delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifePatient Reported Outcome MeasuresImmunotherapy, AdoptivePrecursor Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenNeoplasmsHumansFemaleChildAdolescentSymptom BurdenMaleProspective StudiesAdultYoung AdultLongitudinal StudiesFollow-Up StudiesPrognosis

Stichwörter der Autor:innen

CAR T‐cell therapypatient‐reported outcomesquality of life

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • MACC Fund Center for Cancer and Blood Disorders, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Bioinformatics and Quantitative Child Health, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Cancer and Blood Disorders Center, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
  • Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
  • Novartis, East Hanover, New Jersey, USA.
  • Department of Psychosocial Oncology and Palliative Care, Dana-Farber Cancer Institute, Boston, Massachusetts, USA.

ORCID-Profile: Angela Steineck, Mallory R Taylor, Lori Wiener

Förderung

  • T32 Training
  • St. Baldrick's Foundation
  • NCI NIH HHS
  • NIH HHS
  • ALSAC
  • NHLBI NIH HHS
  • Conquer Cancer Foundation
  • National Cancer Institute

Zitieren

APA

Steineck, A., Zhang, L., Pan, A. Y., Taylor, M. R., Silbert, S. K., Shalabi, H., Comiskey, L., Knight, J. M., Wiener, L., & Levine, D. (2026). Health‐Related Quality of Life and Symptom Burden in Pediatric Patients Receiving CAR T‐Cell Therapy: A Prospective, Longitudinal Patient‐Reported Outcomes Study. Pediatric Blood & Cancer, 73(10). https://doi.org/10.1002/1545-5017.70589

Vancouver

Steineck A, Zhang L, Pan AY, Taylor MR, Silbert SK, Shalabi H, et al. Health‐Related Quality of Life and Symptom Burden in Pediatric Patients Receiving CAR T‐Cell Therapy: A Prospective, Longitudinal Patient‐Reported Outcomes Study. Pediatric Blood & Cancer. 2026;73(10). doi:10.1002/1545-5017.70589

BibTeX
@article{Steineck2026,
  author = {Steineck, Angela and Zhang, Liyun and Pan, Amy Y and Taylor, Mallory R and Silbert, Sara K and Shalabi, Haneen and Comiskey, Liam and Knight, Jennifer M and Wiener, Lori and Levine, Deena},
  title = {Health‐Related Quality of Life and Symptom Burden in Pediatric Patients Receiving CAR T‐Cell Therapy: A Prospective, Longitudinal Patient‐Reported Outcomes Study},
  journal = {Pediatric Blood & Cancer},
  year = {2026},
  volume = {73},
  number = {10},
  doi = {10.1002/1545-5017.70589}
}
Kostenlos starten →